Xeomin vs Botox: What the Research Shows and How to Choose

Xeomin vs Botox is a common question, often from people who have heard that one is “purer” or lasts longer. In this guide I explain what the FDA labels say about each product, what head-to-head studies found, where the “naked toxin” and antibody claims stand, and what that means when you are choosing. At KORA we offer Botox, Dysport and Daxxify; if you want Xeomin specifically, ask whether Xeomin is available when you book.

What Xeomin and Botox have in common

Xeomin (incobotulinumtoxinA) and Botox Cosmetic (onabotulinumtoxinA) are both botulinum toxin type A, and both work the same way: they block the nerve signal that tells a muscle to contract, so the skin above it stops creasing. Since July 2024 they also share the same FDA-approved cosmetic areas for the upper face. Merz announced that month that Xeomin was approved for forehead lines, frown lines and crow’s feet together, based on two phase 3 trials in 730 adults. Botox Cosmetic is approved for the same three areas and, since its label update in October 2024, for platysma bands in the neck as well.

The labeled doses are the same on paper: 20 units for frown lines, 20 units for the forehead given together with the frown lines, and 24 units for crow’s feet. That does not make the units the same thing. Xeomin’s label states that its units “cannot be compared to or converted into Units of any other botulinum toxin products,” and the Botox Cosmetic label says it “is not equivalent to other preparations of botulinum toxin products.” Each company measures potency with its own test. In practice, as the studies below show, Xeomin and Botox are usually dosed at about the same number of units.

	Xeomin	Botox Cosmetic
FDA-approved cosmetic areas	Frown lines, forehead lines, crow’s feet	Frown lines, forehead lines, crow’s feet, platysma bands
Labeled dose for frown lines	20 units	20 units
Accessory proteins	None; the label describes the toxin “without accessory proteins”	Present; the label describes a complex of the neurotoxin and “several accessory proteins”
Storage before mixing	At or below 25 C; refrigeration not required	Refrigerated, 2 to 8 C
Retreatment interval on the label	No more often than every 3 months	Not studied more often than every 3 months

What head-to-head studies found

When Xeomin and Botox have been compared directly at the same dose, they have performed about the same. A randomized trial led by Kane and colleagues and published in Dermatologic Surgery in 2015, randomized 250 women aged 18 to 50 with moderate to severe frown lines to 20 units of either product. Neither the patients nor the assessors knew which one was used. The two were equally effective at one month, the main endpoint, and had similar results and side effects through four months. The study was funded by Merz, the maker of Xeomin, which is worth knowing; its result was equivalence, not superiority.

A 2012 meta-analysis in the Journal of Drugs in Dermatology by Jandhyala pooled 11 studies that compared the two products. At 24 units, Xeomin had a 94 percent statistical likelihood of being slightly more effective, but the author judged the difference not clinically meaningful and concluded the two should be treated as equally potent unless better evidence appears. In practical terms, unit for unit, you can expect a similar effect.

You may see different success rates on the two labels, for example 67 and 58 percent for Xeomin on forehead lines and 61 and 46 percent for Botox. Those numbers come from separate trials with different patients and different scoring rules, so they cannot be compared with each other. Only a head-to-head trial answers which works better, and those trials point to a tie.

The “naked toxin” and the antibody question

The real manufacturing difference is that Xeomin is purified down to the toxin alone, while Botox keeps accessory proteins around it. The theory is that fewer foreign proteins give the immune system less to react to, so the body is less likely to make neutralizing antibodies that stop the toxin working.

What the research shows is that this is uncommon with either product at cosmetic doses. A 2024 literature review in the journal Life by Lee and colleagues reported that across 13 Xeomin facial-line trials in 4,435 patients, 0.5 percent developed antibodies, most of them non-neutralizing, at a rate similar to placebo. The Botox Cosmetic label reports that in its crow’s feet trials, 1.5 percent of 916 patients developed binding antibodies and none developed neutralizing antibodies. The same review found that the factors linked to antibodies are mostly high cumulative doses, large doses per session and injections given close together, and most of that evidence comes from medical uses such as spasticity, where doses are far higher than for wrinkles.

Onset, duration and how they feel

Onset and duration are similar enough that your own muscles matter more than the brand. The Botox Cosmetic label says the effect usually begins one to two days after injection, builds through the first week, and lasts about three to four months for frown lines. In the 2015 head-to-head trial, results tracked closely for both products through four months. How long it lasts for you depends more on your muscles and your dose than on the brand, which I explain in our Botox timeline guide.

The appointment itself feels the same: a few small injections, a short pinch with each, and no recovery time beyond the usual aftercare. Storage is a clinic matter rather than a patient one. Xeomin can sit at room temperature before it is mixed, while Botox must be refrigerated; once either is prepared, it is handled the same way.

How to choose between Xeomin, Botox and the alternatives

For most people, the injector’s plan for your muscles matters more than which of these two products is in the syringe. These are the questions I would bring to a consultation:

• “Which product have I had before, and how did it work?”Bring the name and number of units from past treatments if you have them. A good past response is a reason to stay with it.
• “Is the area I want treated FDA-approved for this product?”Frown lines, forehead lines and crow’s feet are approved for both. Other areas, such as the jaw or the lip, are off-label for both.
• “How many units, and how often?”Units are not interchangeable between brands, so compare plans, not unit counts. Both labels set three months as the minimum interval that has been studied.
• “Would a longer-lasting option suit me better?”Daxxify is FDA-approved for frown lines at 40 units, and its label trials followed patients for at least 24 weeks. Ask whether a longer-acting product suits your schedule.

If you are comparing Botox with Dysport as well, my Dysport vs Botox guide covers how the unit conversion works and what head-to-head trials found.

What it costs at KORA

Because units differ between brands, a price per unit only means something next to the number of units your plan needs.

Prices come from our current price list. Your plan and total are confirmed at a complimentary consultation before anything begins.

Read more about Botox and Daxxify at our clinic on the Scottsdale and Paradise Valley border, or see how many units of Botox common areas need.